Stocks
Protalix BioTherapeutics, Inc.PLX
AMEXHealthcareBiotechnology$3.05
Price as of · delayed, not real-time
A biopharmaceutical company focused on developing and commercializing recombinant therapeutic proteins based on its proprietary plant cell-based expression system. Its lead product, taliglucerase alfa, is an enzyme replacement therapy for Gaucher disease, and the company has a pipeline of additional candidates targeting other lysosomal storage disorders. Investors track Protalix for its niche manufacturing platform and its commercial partnership with Pfizer.
52W Range: $1.65-$3.19
Congressional Interest in Protalix BioTherapeutics, Inc. (PLX)
1 member of Congress has disclosed 2 trades in Protalix BioTherapeutics, Inc. (PLX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
1
Buys
1
Sells
1
Who in Congress Is Trading PLX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2011-11-05 | JAMES B. RENACCI | buy | $1,104.81 |
| 2011-09-05 | JAMES B. RENACCI | sell | $7,958.60 |